Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Sherie L. Morrison, Ph.D.
Sherie L. Morrison, Ph.D.


Professor, Department of Microbiology, Immunology and Molecular Genetics
Member, JCCC Tumor Immunology Program Area

Contact Information:

(310) 206-5124

Scientific Interest(s):

Antibodies are molecules that play a critical role in providing protection against infectious disease. They also are thought to be important for prevention or treatment of cancer and potentially important weapons in the fight against bioterrorism. Dr. Sherie Morrison's laboratory has pioneered the development of genetically engineered antibodies for many applications. Presently, the laboratory is investigating the role of antibodies in treating fungal and viral infections. The lab's researchers are developing antibodies to provide protection against botulinum toxin, a deadly toxin that is the cause of botulism and a potential weapon of terrorists. Antibody fusion proteins also are being developed for the treatment of malignancy.

Selected Cancer-Related Publications:

Cho JS, Hsu JV, Morrison SL. Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity. Cancer Immunol Immunother. 2009 Jul;58(7):1057-69. Epub 2008 Nov 19.

Huang TH, Chintalacharuvu KR, Morrison SL. Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities. J Immunol. 2007 Nov 15;179(10):6881-8.

Huang TH, Morrison SL. A trimeric anti-HER2/neu ScFv and tumor necrosis factor-alpha fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia. J Pharmacol Exp Ther. 2006; 316(3): 983-91.

Ng PP, Helguera G, Daniels TR, Lomas SZ, Rodriguez JA, Schiller G, Bonavida B, Morrison SL, Penichet ML. Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood. 2006; 108(8): 2745-54.

Asai T, Trinh R, Ng PP, Penichet ML, Wims LA, Morrison SL. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery. Biomol Eng. 2005; 21(6): 145-55.